Increased competition is affecting epinephrine vial and glucagon markets ... we’re kind of famous for being one of the first to get enoxaparin approved. We’ve used those learnings to then ...

Offsetting these growth trends will be sales declines due to increased competition for glucagon, epinephrine, phytonadione and enoxaparin ... and the multi-dose vial. And now there’s 4 or ...

Unlike unfractionated heparin (UFH), the low-molecular-weight heparin enoxaparin (Lovenox) is excreted mainly by the kidneys. To determine whether this characteristic heightens bleeding risk in ...

Nick Blackmer is a librarian, fact-checker, and researcher with more than 20 years of experience in consumer-facing health and wellness content. Eli Lilly has reduced the prices of certain ...

Eli Lilly said Tuesday that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells, as the pharma giant seeks to draw patients away from ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. A bunch of people I know (including me) have gotten sick ...

OBJECTIVE: To document the efficacy of a surgical intensive care unit (SICU)- specific, weight-based dosing protocol of enoxaparin 0.5 mg/kg given subcutaneously every 12 hours for VTE prophylaxis ...

Lilly said patients must refill their prescriptions of the two higher-dose vials within 45 days of their first fill to get the same pricing, and would otherwise have to pay as much as $699 for ...

Shares of the Indianapolis-based drugmaker rose 2.3% to $902.42. The launch of Lilly's vials expands options for patients who choose to pay cash through the drugmaker's direct-to-consumer website ...

Police allegedly found the vial after Mr Nadir and Sarah Abu Lebdeh were stood down from their roles at Bankstown Hospital following the emergence of the video, 7NEWS reported. After Mr Nadir ...

Amphastar Pharmaceuticals (NASDAQ:AMPH) reported its fourth-quarter 2024 earnings, falling short of analyst expectations with an EPS of $0.92 against a forecast of $0.97. Revenue also missed ...